KDR (kinase domain receptor), also known as VEGFR2 or Flk-1, is a tyrosine kinase receptor for vascular endothelial growth factor (VEGF) and plays a key role in angiogenesis. While KDR mutations are rare, amplification or protein overexpression have been reported in small proportion of a variety of solid tumors. Genetic alteration in KDR have been identified in 10% of lung adenocarcinomas. KDR (VEGFR2) R962H lies within the protein kinase domain of the KDR. This variant has not been biochemically characterized; however, mutations in this locus have been identified in various tumor types. Most therapies blocking KDR signaling target the angiogenesis pathway in general, such as bevacizumab, an antibody that targets VEGF-A. These results should be interpreted in the clinical context.